<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866369</url>
  </required_header>
  <id_info>
    <org_study_id>337HVPK18007</org_study_id>
    <secondary_id>2018-003822-99</secondary_id>
    <nct_id>NCT03866369</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define Lanifibranor (IVA337) Supra-therapeutic Dose in a Multiple Dosing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventiva Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inventiva Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a double-blind, randomized, placebo-controlled, multiple ascending dose&#xD;
      study with lanifibranor. The study will consist of up to 3 cohorts of 12 subjects each;&#xD;
      therefore, approximately 36 subjects will be included in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subject will receive first a single dose of 400 mg moxifloxacin, under open-label fasting&#xD;
      conditions at Day -8 (assay sensitivity).&#xD;
&#xD;
      Following, all subjects also will receive a dose of placebo under open-label fasting&#xD;
      conditions at D-1.&#xD;
&#xD;
      In the morning of Day 1, subjects will be randomized to either the investigational medicinal&#xD;
      product (IMP) or placebo (3:1). The treatment phase last 14 days and the end of study visit&#xD;
      will occurs within 5 to 9 days after the last dose of IMP or placebo (or at early&#xD;
      termination)&#xD;
&#xD;
      A staggered dose approach will be applied within each subjects cohort with 48 hours of delay&#xD;
      between subcohorts.&#xD;
&#xD;
      A sefty review committe (SRC) will review after each cohorts all available safety and PK data&#xD;
      under blinded conditions and conclude the safety and tolerability of the dose level before&#xD;
      proceeding to the next dose level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">August 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Multiple ascending dose study with 3 sequential cohorts of 12 subjects treated by Lanifibranor versus Placebo during 14 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of abnormal Vital signs (blood pressure, pulse) and physical exams</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of abnormal Clinical laboratory tests (chemistry, hematology, urinalysis)</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of abnormal 12-lead digital electrocardiograms parameters (Heart rate, QT/QTc interval, PR interval, QRS interval, RR interval) change from baseline</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of lanifibranor and its metabolites</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum plasma concentration (Tmax) of lanifibranor and its metabolites</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC0-t) of lanifibranor and its metabolites</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiovascular safety events</measure>
    <time_frame>From Baseline up to 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMP Under investigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to Match</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Single oral dose at D-8</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo to Match</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral dose at D-1</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo to Match</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanifibranor</intervention_name>
    <description>Single daily oral dose during 14 days</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single daily oral dose during 14 days</description>
    <arm_group_label>Placebo to Match</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:&#xD;
&#xD;
        Subject voluntarily agrees to participate in this study and signs an IEC-approved informed&#xD;
        consent prior to performing any of the Screening Visit procedures.&#xD;
&#xD;
        2. Males between 18 to 55 years of age (inclusive) 3. Nonsmokers (or other nicotine use) as&#xD;
        determined by history (no nicotine use over the past 3 months) and by urine cotinine&#xD;
        concentration (&lt; 500 ng/mL) at the Screening Visit and admission.&#xD;
&#xD;
        4. Body mass index (BMI) between 18.0 and 29.9 kg/m2 (inclusive) at the Screening Visit.&#xD;
&#xD;
        5. Healthy with no clinically relevant deviation or finding in medical history, physical&#xD;
        examinations, vital signs or 12-lead ECGs at the Screening Visit or admission, as&#xD;
        applicable. Clinical laboratory values at the Screening Visit or admission should be within&#xD;
        normal limits or judged not clinically significant as determined by the Investigator and&#xD;
        with liver values such as:&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≤ 1.1 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤ 1.2 × ULN&#xD;
&#xD;
          -  Gamma-glutamyltransferase (GGT) ≤ 1.5 × ULN&#xD;
&#xD;
          -  Alkaline phosphatase (ALP) ≤ 1.5 × ULN&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          1. History or evidence of any relevant cardiovascular, gastrointestinal, endocrinologic,&#xD;
             hematologic, hepatic, immunologic, metabolic (e.g., diabetes), urologic, pulmonary,&#xD;
             neurologic, psychiatric, dermatologic, renal (e.g., renal insufficiency), and/or other&#xD;
             major disease or malignancy (e.g., bladder cancer) or present infectious disease as&#xD;
             judged by the Investigator.&#xD;
&#xD;
          2. Subject has any surgical or medical condition that would interfere with the&#xD;
             absorption, distribution, metabolism or excretion of drugs, or which may jeopardize&#xD;
             the subject in case of participation in the study.&#xD;
&#xD;
               1. Inflammatory bowel disease, peptic ulcers, gastrointestinal including rectal&#xD;
                  bleeding.&#xD;
&#xD;
               2. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or&#xD;
                  bowel resection.&#xD;
&#xD;
               3. Pancreatic injury or pancreatitis within 12 months prior to Screening.&#xD;
&#xD;
               4. Liver disease or liver injury as indicated by abnormally increased liver function&#xD;
                  tests. ALT, AST, GGT, ALP, and serum bilirubin will be tested at Screening.&#xD;
&#xD;
                    -  Any single parameter of ALT, AST, GGT, or ALP must not exceed 1.1 x ULN and&#xD;
                       ≥ 1.2 x ULN total bilirubin.&#xD;
&#xD;
                    -  Any elevation above ULN of more than one parameter of ALT, AST, GGT, ALP, or&#xD;
                       serum bilirubin will exclude a subject from participation in the study.&#xD;
&#xD;
                  If necessary, laboratory testing may be repeated on one occasion (as soon as&#xD;
                  possible) prior to randomization, to rule out any laboratory error.&#xD;
&#xD;
               5. History or presence of impaired renal function as indicated by clinically&#xD;
                  significantly abnormal creatinine or blood urea nitrogen and/or urea values, or&#xD;
                  abnormal urinary constituents (e.g. albuminuria).&#xD;
&#xD;
               6. Evidence of urinary obstruction or difficulty in voiding&#xD;
&#xD;
               7. History of immunodeficiency diseases.&#xD;
&#xD;
               8. Blood levels of sodium, potassium, calcium, or magnesium outside of laboratory&#xD;
                  normal range at Screening and baseline.&#xD;
&#xD;
               9. TSH outside of laboratory normal range at Screening.&#xD;
&#xD;
          3. Subject has any concurrent disease or condition that, in the opinion of the Principal&#xD;
             Investigator, would make the subject unsuitable for participation in the clinical&#xD;
             study.&#xD;
&#xD;
          4. Subject has a pulse &lt; 50 beats per minute (bpm) or &gt; 90 bpm; systolic BP &lt; 90 mmHg or&#xD;
             &gt; 140 mmHg; diastolic BP &lt; 50 mmHg or &gt; 90 mmHg at the Screening Visit. One re-test is&#xD;
             allowed, if (a) test result(s) is outside these limits.&#xD;
&#xD;
          5. Abnormal 12-lead ECG at the Screening Visit or admission, including:&#xD;
&#xD;
               -  Uncorrected QT interval ≥ 500 msec&#xD;
&#xD;
               -  QTcF &gt; 450 msec&#xD;
&#xD;
               -  QRS interval &gt;120 msec&#xD;
&#xD;
               -  PR interval &gt;220 msec&#xD;
&#xD;
               -  Second or third-degree atrio-ventricular block&#xD;
&#xD;
               -  Any rhythm other than sinus rhythm, which is interpreted by the Investigator to&#xD;
                  be clinically significant&#xD;
&#xD;
          6. Subject has clinically significant conduction disorders, significant arrhythmia or a&#xD;
             known risk from medical history to not respond to moxifloxacin.&#xD;
&#xD;
          7. Subject has a history of additional risk factors for &quot;Torsades de Pointe&quot; (e.g., heart&#xD;
             failure, hypokalemia [below the lower limit of normal], family history of Long QT&#xD;
             Syndrome).&#xD;
&#xD;
          8. Family history of QTc prolongation or of unexplainable sudden death at &lt; 50 years of&#xD;
             age.&#xD;
&#xD;
          9. Any contraindication or reasons for precautionary use of moxifloxacin such as:&#xD;
&#xD;
               -  History of allergy/phototoxicity with quinolone group of drugs in the last year&#xD;
                  prior to Screening.&#xD;
&#xD;
               -  History of peripheral neuropathy.&#xD;
&#xD;
               -  History of tendinitis, tendon rupture, or clinically significant tendon injury.&#xD;
&#xD;
               -  Risk factor associated with psychiatric reactions.&#xD;
&#xD;
               -  History of seizure disorders or disease which can lower seizure threshold.&#xD;
&#xD;
         10. Subject has a history or family history of G6PD or any other congenital hemolytic&#xD;
             anemias.&#xD;
&#xD;
         11. Subject has history of illicit drug abuse.&#xD;
&#xD;
         12. Subject has a history of drinking &gt; 168 g pure alcohol per week (10 g pure alcohol =&#xD;
             259 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 2 years&#xD;
             prior to the first admission to the clinical unit.&#xD;
&#xD;
         13. Subject has positive test for hepatitis B surface antigen (HBsAg), hepatitis B core&#xD;
             antibody (anti-HBc), hepatitis C antibody (anti-HCV) or human immunodeficiency virus&#xD;
             (HIV) antibodies (types 1 and 2) at the Screening Visit.&#xD;
&#xD;
         14. Subject has positive alcohol test at the Screening Visit or admission.&#xD;
&#xD;
         15. Subject has positive urine drug test (e.g., cocaine, amphetamines, barbiturates,&#xD;
             opiates, benzodiazepines, cannabinoids) at the Screening Visit or admission.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy male volunteers</keyword>
  <keyword>multiple ascending dose</keyword>
  <keyword>supra-therapeutic dose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

